AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% FDC 3.33 ▼-1.19% KOA 3.10 ▲1.64%

AT1 Atomo Diagnostics Limited

Healthcare · Medical Devices · website
$0.02
52wk 0.02 – 0.05
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Atomo Diagnostics Limited

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$16.24M
P/E (trailing)
P/E (forward)
-0.02
EPS (trailing)
-0.01
Dividend yield
Payout ratio
0.0%
Beta
1.10
EV / EBITDA
-2.50
Price / Book
2.25
ROE
-56.6%
Operating margin
-111.7%
Net margin
-101.4%
Total cash
$3.51M
Total debt
$500,513
Current ratio
2.78
Debt / Equity
0.08
Free cash flow
$-1.40M
Avg volume
1.12M
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$3.25M
  • Gross profit$1.38M
  • Operating income-$7.01M
  • Net income-$4.97M
  • Diluted EPS-0.01
  • Free cash flow-$1.99M
  • Net debt-$3.03M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9